Verona Pharma to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update

Rhea-AI Summary

Verona Pharma (Nasdaq: VRNA) will report its fourth quarter and full year financial results for 2020 on February 25, 2021. A conference call for investors will take place at 9:00 a.m. EST / 2:00 p.m. GMT to discuss these results and provide a corporate update. The company is known for developing therapies for respiratory diseases, notably ensifentrine, which is in Phase 3 trials for COPD treatment. The funds from a $200 million private placement in July 2020 are expected to support operations into 2023.

Positive

• Engaged in promising Phase 3 clinical program for ensifentrine, aimed at COPD treatment.
• Successfully raised $200 million through private placement in July 2020 to fund operations until 2023.

Negative

• None.

LONDON and RALEIGH, N.C., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the fourth quarter and full year ended December 31, 2020 on Thursday, February 25, 2021 and host an investment community conference call at 9:00 a.m. EST / 2:00 p.m. GMT to discuss these financial results and provide a corporate update.

To participate, please dial one of the following numbers and reference conference ID 7681320:

• +1-888-317-6003 for callers in the United States
• +1-412-317-6061 for international callers

A live webcast will be available on the Events and Presentations link on the Investors page of the Company’s website, www.veronapharma.com, and an audio replay will be available there for 90 days.

For further information, please contact:

Verona Pharma plc	US Tel: +1-833-417-0262 UK Tel: +44 (0)20 3283 4200
Victoria Stewart, Director of Communications	info@veronapharma.com
Argot Partners (US Investor Enquiries)	Tel: +1 212-600-1902 verona@argotpartners.com
Kimberly Minarovich / Michael Barron
Optimum Strategic Communications (International Media and European Investor Enquiries)	Tel: +44 (0)203 950 9144 verona@optimumcomms.com
Mary Clark / Eva Haas / Shabnam Bashir

About Verona Pharma

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. If successfully developed and approved, Verona Pharma’s product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The Company is evaluating nebulized ensifentrine in its Phase 3 clinical program ENHANCE (“Ensifentrine as a Novel inHAled Nebulized COPD thErapy”) for COPD maintenance treatment. The Company raised gross proceeds of $200 million through a private placement in July 2020 and expects the funds to support its operations and Phase 3 clinical program into 2023. Two additional formulations of ensifentrine are currently in Phase 2 development for the treatment of COPD: dry powder inhaler (“DPI”) and pressurized metered-dose inhaler (“pMDI”). Ensifentrine is being evaluated in a pilot clinical study in patients hospitalized with COVID-19 and has potential applications in cystic fibrosis, asthma and other respiratory diseases. For more information, please visit www.veronapharma.com.

 

FAQ

When will Verona Pharma announce its financial results for 2020?

Verona Pharma will announce its financial results for the fourth quarter and full year on February 25, 2021.

What product is Verona Pharma developing for respiratory diseases?

Verona Pharma is developing ensifentrine, which is in Phase 3 trials for the treatment of COPD.

What is the significance of the $200 million raised by Verona Pharma?

The $200 million raised is intended to support Verona Pharma's operations and clinical programs into 2023.